← SynDRA
ABACAVIR
SynDRA canonical compound SYN0005878 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Mechanism of action | nucleoside reverse transcriptase inhibitor |
|---|
| Indication | human immunodeficiency virus (HIV-1) |
|---|
| Disease area | infectious disease |
|---|
All known targets
- HIV RT
- gag-pol
- pol
- reverse transcriptas
Mechanisms of action (all sources)
- nucleoside reverse transcriptase inhibitor
- HIV RT INHIBITOR
- pol INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- PDE4D
- NR1I2
- ABCB1
- MAPDA
- MAOA
- KCNH2
- HTR3A
- HTR2C
- HTR2B
- MLNR
- HTR2A
- HTR1A
- HRH3
- HRH2
- HRH1
- HDAC6
- MC3R
- NPY1R
- ABCC1
- NR3C1
- OPRD1
- OPRK1
- OPRM1
- PDE3A
- PGR
- PTGS2
- SAMHD1
- SLC29A1
- SLC6A2
- SLC6A3
- SLC6A4
- GHSR
- EHMT2
- EDNRA
- AVPR1A
- ABCC2
- ABCC3
- ADORA1
- ADORA2A
- ADORA3
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Nucleoside Reverse Transcriptase Inhibitors
- Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
- Anti-HIV Agents
- Anti-Infective Agents
- Anti-Retroviral Agents
- Antiviral Agents
- Enzyme Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Reverse Transcriptase Inhibitors
- Cytochrome P450 1A1 Inhibitors
ATC classes
- J05A · DIRECT ACTING ANTIVIRALS
Cross-references
Synonyms
- ABACAVIR SULFATE
- ABACAVIR SULFATE AND LAMIVUDINE
- ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE
- EPZICOM
- TRIUMEQ
- TRIUMEQ PD
- TRIZIVIR
- ZIAGEN
- Ziagen
- 1592U89
- abacavir sulfate
- ziagen
- abacavir succinate
- Avacavir
- Epzicom
- NSC-742406
- Trizivir
- Abacavir [INN]
- Abacavir (INN)
- Ziagen (TN)
- Ziagen (TM)(*Succinate salt*)
- (+/-)-Abacavir
- ABC
- NSC 742406
- WR2TIP26VS
- CHEBI:421707
- abacavirum
- (+)-abacavir sulfate
- RefChem:551202
- (1R,4S)-abacavir sulfate
- J05AF06
- DTXCID601478426
- MFCD00903850
- Abacavir (1.0 mg/mL in Methanol)
- Abacavir [INN:BAN]
- UNII-WR2TIP26VS
- NSC742406
- NCGC00164560-01
Reported adverse events
- Hypersensitivity
- Lactic acidosis
- Hepatomegaly
- Lactic acid
- Hepatitis
- Hepatitis B
- Acidosis
- P
- Se
- Myopathy
- DIC
- UTI
Look up ABACAVIR in the interactive SynDRA portal →